H/T Flag And Cross.
This is some really big news.
Kaiser Permanente Washington Health Research Institute in Seattle is, according to new reports, ready to administer first experimental dose of coronavirus vaccine to its first participant in a clinical trial on Monday.
This is huge news as it could mean first steps in truly getting a handle on the virus that is currently wreaking havoc across the country and the rest of the world.
Check out the details from Yahoo News:
Kaiser Permanente’s Phase 1 clinical trial is the first U.S. study focusing on a potential vaccine for the virus that so far has killed at least 69 Americans and more than 6,500 elsewhere in the world. The test makes use of Moderna’s mRNA-1273 vaccine.
The call went out this month to recruit 45 healthy Seattle-area adults between 18 and 55 to participate in the study, which is funded by the National Institutes of Health. During this phase of the trial, researchers only want to determine whether the RNA-based vaccine is safe. There’s no risk of infection with the virus at this stage.
Full validation of the vaccine is expected to take a year to 18 months. In the meantime, other research groups around the world are working to develop vaccines. One of those groups, at CureVac in Germany, has become the subject of a controversy over access to its vaccine.
The biggest threat of complications from the coronavirus is for those who have a compromised immune system, such as sufferers of diabetes, or those who are elderly. Much of the hoopla surrounding the illness is geared toward protecting this particular group of individuals.
Now, with this potential vaccine, things could really turn around. If it’s successful. Let’s hope that’s the case so that this thing can get controlled and we can all get back to living our normal lives.